Association of Serotonin$_{2C}$ Receptor Polymorphisms With Antipsychotic Drug Response in Schizophrenia

Jiang Li$^1$, Hitoshi Hashimoto$^{1,2,3,4,5,6}$ and Herbert Y. Meltzer$^1$*

$^1$ Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Evanston, IL, United States, $^2$ Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Japan, $^3$ Molecular Research Center for Children’s Mental Development, United Graduate School of Child Development, Osaka University, Kanazawa University, Hamamatsu University School of Medicine, Chiba University and University of Fukui, Osaka University, Suita, Japan, $^4$ iPS Cell-based Research Project on Brain Neuropharmacology and Toxicology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Japan, $^5$ Division of Bioscience, Institute for Datability Science, Osaka University, Suita, Japan, $^6$ Transdimensional Life Imaging Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Japan

There is conflicting evidence for the association between genetic polymorphisms in the serotonin (5-HT)$_{2C}$ receptor (HTR2C) and response to antipsychotic drugs (APD) in schizophrenic patients. We tested the association between the HTR2C polymorphisms, Cys23Ser, −759C/T, and −697G/C, and response to APDs (mainly clozapine) in a 6 month prospective study in 171 patients with schizophrenia. Ser23 was significantly associated with treatment response (positive symptoms, $X^2 = 7.540$, $p = 0.01$; negative symptoms, $X^2 = 4.796$, $p = 0.03$) in male patients only. A −759C-Ser23 haplotype was similar associated with positive ($X^2 = 6.648$, $p = 0.01$) and negative ($X^2 = 6.702$, $p = 0.01$) symptom improvement. Logistic regression, after controlling for covariates, also showed significant haplotypic associations. A meta-analysis of six studies for Ser23 and treatment response showed an overall odds ratio of 2.00 (95%CI, 1.38–2.91, $p = 0.0003$) or 1.94 (95%CI, 1.27–2.99, $p = 0.0024$) under fixed or random effect models. These results provide additional evidence that HTR2C polymorphisms are associated with treatment response to APD with HTR2C antagonism or inverse agonism, in male schizophrenic patients.

Keywords: serotonin$_{2C}$, schizophrenia, genetic, treatment response, antipsychotic agents, clozapine, meta-analysis, polymorphism

INTRODUCTION

The serotonin (5-HT)$_{2C}$ receptor (HTR2C), located at Xq24, belongs to the seven-transmembrane-spanning G protein–coupled receptor superfamily. It is widely distributed in brain regions which are relevant to schizophrenia. HTR2C receptors exert a tonic inhibitory effect on dorsal and ventral striatal, limbic, hippocampal, and cortical dopamine (DA) release (1, 2), modulate serotoninergic activity in the dorsal raphe (3), and regulate 5-HT and glutamate efflux in rat cortex (4). HTR2C is involved in the neurobiology of schizophrenia and the efficacy and side effects of some APDs. It is one of the key regulators of dopaminergic activity in the limbic system. Stimulation of DA D2 receptors in the ventral and dorsal striatum can lead to delusions and hallucinations (5). Activation of HTR2C receptors might lead to decreases in DA release...
in key brain regions for schizophrenia (6). HTR2C are expressed on principal neurons and GABAergic interneurons in the prefrontal cortex (7) and, thus, may be relevant to the hypoglutamatergic basis for various components of the schizophrenia syndrome (8). The ability of 5-HT-stimulated and constitutively active HTR2C receptors to inhibit DA release in limbic brain areas has been postulated to cause psychosis and to modulate the efficacy of APDs that act by blocking DA D2 receptors (9–12). Blockade of the constitutive activity of HTR2C receptors enhances cortical and limbic DA release by some APDs (12). The ability of HTR2C agonists to reduce DA release from terminals of VTA neurons in mesolimbic areas is consistent with the antipsychotic effect of the HTR2C agonist, vabicaserin (13, 14). Vabicaserin is effective in reversal of phencyclidine and amphetamine-induced hyperactivity (15).

Evidence from genetic association studies also implicates HTR2C in a variety of neuropsychiatric diseases. The HTR2C has a well-characterized promoter region harboring multiple polymorphisms (Figure 1A), suggesting their potential impact on CpG methylation and putative transcription factor binding, resulting in alteration of HTR2C expression. −759C/T and −697G/C are the most widely investigated promoter polymorphisms. −759C/T polymorphism is associated with antipsychotic induced weight gain (17). −759C/T or −697G/C, has also been linked to therapeutic response to APDs (18–20). However, these results are contradictory to each other with regard to gender and risk allele.

Cys23Ser, is a non-synonymous SNP which results in an amino acid substitution of cysteine to serine at position 23. This substitution can disrupt a disulfide bridge and potentially alter the structure or stability of the HTR2C protein (21). Although this functional polymorphism has been found to be associated with numerous neuropsychiatric diseases, including anorexia nervosa (22), unipolar, and bipolar depression (16, 23), psychotic symptoms in late-onset Alzheimer's disease (24), vulnerability to cocaine cue reactivity (25), migraine with aura (26), and stress-related cortisol levels (27), it’s association with schizophrenia is less clear (28). An association between the Cys23Ser and visual hallucinations and depression in schizophrenia patients has been reported (24), but has not been replicated by others (29, 30). Cys23Ser is associated with chronic hospitalization in schizophrenia patients (31) and APD-induce extrapyramidal side effects (32) suggests it is more related to the impact of treatment on the disease process, possibly through effects on dopaminergic activity. Most importantly for this study, Cys23Ser has also been linked in some (33, 34) but not all studies (35–37) to the extent of response to clozapine. These studies will be the subject of a meta-analysis included in the Results section. Clozapine response in treatment-resistant schizophrenia patients does not occur within the conventional 6 week clinical trial period in many patients (38, 39). Due to the inconsistent relationship between HTR2C polymorphisms and the psychopathology of schizophrenia, the response to clozapine, and functional activity assays, we examine all three widely-investigated HTR2C SNPs as possible predictors of response of positive and negative symptoms to APD treatment in schizophrenia. Male and female subjects were analyzed separately in order to determine a possible association with gender. Finally, a meta-analysis was performed to determine the overall association between HTR2C polymorphisms and response to clozapine and other APDs.

MATERIALS AND METHODS

Subjects

The 171 (male/female, 115/56) patients with schizophrenia or schizoaffective disorder who participated in this study were part of an NIMH-sponsored extramural clinical research center at Case Western Reserve University School of Medicine and Vanderbilt University School of Medicine. Details about recruitment and assessment of subjects have been reported previously (40). Categorical treatment response was evaluated at 6 week and 6 months, using the criteria based upon Kane et al. (41). Subjects with a reduction of >20% in the Brief Psychiatric Rating Scale (BPRS) total score or subcategories, BPRS Positive and Negative, was defined as a responder. Patients were treated with standard doses of the following atypical antipsychotic drugs: clozapine, 550 mg(400–900 mg), 78%; melperone, 250 mg(100–400 mg), 7.0%; risperidone, 6 mg(4–8 mg), 3.8%; or olanzapine, 20 mg(15–40 mg), 2.1%, or typical antipsychotic drugs, mainly haloperidol (10 mg, 9.0%). Antidepressants (14%) and mood stabilizers (5%) were used sparingly.

Genotyping

Taqman® assay for three SNPs, −759C/T(rs3813929), −697G/C(rs518147), and Cys23Ser(rs6318) was performed at Northwestern University Genomic Core. Call rates are 95.32, 98.83, and 97.66%, respectively. The linkage disequilibrium (LD) and haplotype pattern of genotyped SNPs from our EUR samples (Figure 1C) matched those from 1,000 Genome EUR sample (Figure 1B).

Statistical Analysis (see Supplementary Information for Details)

We analyzed the males and females separately. The relationship between genotypes and demographic variables was analyzed using chi-square (χ²) or ANOVA. Genotype or haplotype associated differential response to APD was initially evaluated by χ² test and then ANCOVA (SPSS), adjusted for race, drugs, age of onset, and the corresponding baseline psychopathology or status of early response. Statistical significance was defined as p < 0.05. As all results were considered exploratory, there was no adjustment for multiple testing. Mapping cis-eQTL or methylation QTL was performed using Braincloud data (42, 43). In order to review and elucidate the general relationship between HTR2C polymorphisms and drug response to APDs, a meta-analysis of six studies, including ours, with accessible genotyping data for Cys23Ser and binary outcome for symptom improvement, were conducted by R “meta” package. Heterogeneity among the studies was assessed by means of the I² inconsistency test and Cochran’s Q statistics under a null hypothesis test in which p < 0.05.
RESULTS
Demographic Data Grouped by Genotypes of Three HTR2C SNPs
Cys23Ser, −759C/T, and −697G/C were genotyped for schizophrenic patients with European (EUR, n = 118) and African (AFR, n = 53) ancestry Table 1. In the male group, the age at onset for the Ser23 carriers was significantly older than that for non-carriers (p = 0.009; Table 1A). This difference was not observed in the females (p = 0.899; Table 1B). There was no significant difference in the proportions of patients who were treatment resistant or unmedicated at baseline between the genotypes for each SNP. Duration of illness and number of previous hospitalization also did not differ. Although Ser23 carriers had a higher total BRPS score in the male patients (p = 0.04), there was no significant difference with regard to the...
TABLE 1 | Demographic information grouped by genotypes of three HTR2C SNPs and separated by gender (1A for Male; 1B for Female).

| SNP ID       | -759C/T(rs3813929) | -697G/C(rs518147) | Cys235er(rs6318) |
|--------------|-------------------|-------------------|------------------|
| SNP ID       | T/T               | C/C               | P-value          | C/C               | G/G               | P-value          | Ser23 carrier | Ser23 non-carrier | P-value |
| A            |                   |                   |                  |                   |                   |                  |               |                  |        |
| Counts       | 17                | 100               | 40               | 77                | 24                | 90               | 0.22          | 0.78             |
| Frequency    | 0.14              | 0.86              | 0.34             | 0.66              | 0.22              | 0.78             |
| Total BPRS   | 27.88 ± 17.51     | 30.57 ± 12.08     | 0.43             | 32.3 ± 14.9       | 29.08 ± 11.78     | 0.2              | 34.92 ± 12.30   | 29.03 ± 12.89   | 0.04   |
| Positive 4 items | 9.41 ± 7.20      | 11.22 ± 5.36      | 0.23             | 11.4 ± 5.74       | 10.73 ± 5.65      | 0.54             | 12.69 ± 4.14    | 10.59 ± 5.81    | 0.09   |
| Positive 3 items | 7.47 ± 5.91      | 9.04 ± 4.72       | 0.23             | 9.28 ± 4.91       | 8.55 ± 4.94       | 0.45             | 10.25 ± 3.53    | 8.57 ± 5.04     | 0.13   |
| Negative 3 items | 3.94 ± 3.33      | 4.43 ± 3.01       | 0.53             | 4.15 ± 2.94       | 4.47 ± 2.91       | 0.98             | 4.65 ± 3.03     | 4.30 ± 2.87     | 0.59   |
| Anxiety/Depression | 4.69 ± 2.87      | 4.99 ± 3.67       | 0.75             | 5.39 ± 3.49       | 4.72 ± 3.59       | 0.30             | 5.24 ± 3.70     | 5.00 ± 3.48     | 0.72   |
| Age of onset (year) | 20 ± 6.24        | 20.26 ± 5.12      | 0.96             | 20.75 ± 6.36      | 19.93 ± 4.60      | 0.43             | 22.78 ± 7.83    | 19.57 ± 4.27    | 0.01   |
| Duration of illness (year) | 11.71 ± 11.34    | 12.21 ± 7.45      | 0.81             | 11.63 ± 9.50      | 12.41 ± 7.26      | 0.62             | 10.61 ± 8.63    | 12.42 ± 8.01    | 0.34   |
| No of previous hospitalization | 4.38 ± 4.24      | 6.66 ± 7.15       | 0.22             | 4.54 ± 4.09       | 7.28 ± 7.78       | 0.05             | 4.76 ± 4.13     | 6.96 ± 6.96     | 0.26   |
| Treatment resistant (%) | 52.9             | 70.0              | 0.17             | 60                | 71.4             | 0.21             | 62.5          | 68.9             | 0.55   |
| Baseline Unmedicated (%) | 81.3             | 76.9              | 0.88             | 78.4             | 77.1             | 0.88             | 72.7          | 78.0             | 0.6    |
| Clozapine treated (%) | 82.4             | 74.0              | 78.7             | 85.0             | 72.7             | 0.34             | 80.3          | 74.4             | 0.28   |
| Ethnicity¹ | 0.004             |                   |                  |                   |                   |                  |               |                  |        |
| EUR          | 12                | 67                | 24               | 55                | 11               | 66               |                |                  |        |
| AFR          | 5                 | 30                | 16               | 22                | 13               | 24               |                |                  |        |
| B            |                   |                   |                  |                   |                   |                  |               |                  |        |
| Counts       | 3                 | 41                | 7                | 24               | 3                 | 33               | 0.38          | 0.62             |
| Frequency    | 0.07              | 0.93              | 0.13             | 0.46             | 0.4              | 1.38             | 0.46          | 0.6             |
| Total BPRS   | 28.33 ± 9.29      | 34.27 ± 11.48     | 0.39             | 30.86 ± 11.86     | 35.71 ± 11.75     | 0.8              | 34.9 ± 14.41    | 33.82 ± 8.40    | 0.73   |
| Positive 4 items | 8.33 ± 6.11      | 12.66 ± 4.52      | 0.12             | 11.14 ± 6.67      | 13.58 ± 4.07      | 0.91             | 12.9 ± 5.18     | 12.15 ± 4.76    | 0.58   |
| Positive 3 items | 7 ± 5.29         | 11.03 ± 3.93      | 0.1              | 10 ± 6.83        | 11.78 ± 3.57      | 0.83             | 11.2 ± 4.95     | 10.3 ± 4.2      | 0.58   |
| Negative 3 items | 3.33 ± 3.22      | 4.39 ± 3.31       | 0.6              | 4 ± 3.74         | 4.5 ± 2.70        | 0.61             | 4.43 ± 3.01     | 4.62 ± 3.46     | 0.84   |
| Anxiety/Depression | 7.33 ± 4.73      | 6.42 ± 4.12       | 0.71             | 6.14 ± 3.33       | 5.75 ± 3.92       | 0.48             | 6.05 ± 3.94     | 6.27 ± 4.03     | 0.85   |
| Age of onset (year) | 20.33 ± 4.04     | 21.55 ± 5.85      | 0.73             | 21 ± 4.08        | 21.30 ± 5.47      | 0.99             | 21.79 ± 4.85    | 21.58 ± 6.27    | 0.9    |
| Duration of illness (year) | 14 ± 15.99       | 11.63 ± 7.27      | 0.62             | 15.29 ± 11.41     | 14.74 ± 7.81      | 0.1              | 13.05 ± 6.96    | 12.49 ± 8.73    | 0.81   |
| No of previous hospitalization | 3 ± 2.83         | 8.11 ± 8.74       | 0.42             | 4.5 ± 3.14       | 7 ± 5.51        | 0.35             | 7.94 ± 9.50    | 7.03 ± 6.79     | 0.71   |
| Treatment resistant (%) | 66.7             | 70.7              | 0.88             | 71.4             | 79.2             | 0.44             | 80           | 69.7             | 0.41   |
| Baseline Unmedicated (%) | 100.0            | 63.6              | 0.29             | 66.7             | 78.9             | 0.49             | 60.0          | 72.4             | 0.4    |
| Clozapine treated (%) | 66.7             | 85.4              | 0.1              | 71.4             | 87.5             | 0.03             | 90.9          | 75.0             | 0.14   |
| Ethnicity¹ | 0.2               |                   |                  |                   |                   |                  |               |                  |        |
| EUR          | 3                 | 26                | 6                | 16               | 12               | 27               |                |                  |        |
| AFR          | 0                 | 15                | 1                | 8                | 8                | 6                |                |                  |        |

The relationship between genotypes and demographic variables was analyzed using chi-square (χ²) or ANOVA. P-values reported are two tailed whenever applicable. Statistical significance was defined as p < 0.05. ¹Self-described ethnicity.
subcategories of psychopathology including positive, negative, and anxiety/depression subscales. Race, drug, age of onset, and baseline psychopathology were included as covariates in the following ANCOVA.

Genotype/Haplotype Associated Differential Response to APDs

We successfully identified the tag SNPs for the candidate SNPs ($r^2 > 0.85$) by SNAP and these tag SNPs are in LD with the three candidates by a haploview analysis of the genotype data from 1,000 Genome Figure 1, Supplementary Table 1. −759C/T, tagged by rs12846241, have been confirmed as cis-eQTL and methylation-QTL for HTR2C (Supplementary Table 2). Cys23Ser, tagged by rs5987834, has no impact on gene expression and % methylation. Based on the previous studies (genetic and functional) and our cis eQTL findings, −759C/T, −697G/C, Cys23Ser, and the combinations of two or all three, were targets for the subsequent genotype-phenotype association study. Since in vitro functional assays indicated that −759C/T and Cys23Ser have a significant impact on HTR2C activity through distinctive mechanisms, we further explored if −759C-Ser, “a super combination,” we propose it produces a greater expression of the constitutively more active form of HTR2C, may demonstrate an even stronger association with dichotomous symptom improvement in an additive mode, after treatment with the APDs, which are HTR2C inverse agonists or antagonists studied here.

A significant association between Cys23Ser and dichotomous treatment response was observed only in the male group for both positive symptoms, $X^2 = 7.540, p = 0.006$; and negative symptoms, $X^2 = 4.796, p = 0.029$, at 6 month (Table 2A). Haplotype analysis showed that −759C-Ser23 maintained the same level of significant association with positive symptom improvement ($X^2 = 6.648, p = 0.010$) and negative symptom improvement ($X^2 = 6.702, p = 0.010$) at 6 month (Table 2A). All of the above significant findings were only observed in the male patients, except for a borderline significance for Cys23Ser associated with negative symptom improvement in female ($X^2 = 3.9, p = 0.048$) at 6 month (Supplementary Table 3).

ANCOVA test on absolute change (Table 2B) or % change in BPRS (data not shown) in symptom improvement after controlling for race, drugs, age of onset, and the corresponding baseline psychopathology indicated that male Ser23 carriers had a significant improvement in positive and negative symptoms ($p = 0.025$ and 0.019, respectively) after 6 months treatment (Table 2B). Neither −759C/T nor −697G/C alone were significantly associated with symptom improvement.

A similar significant association was observed between Cys23Ser and positive/negative symptom improvement in male subjects treated with clozapine only (Supplementary Table 4). Female Ser23 carriers also showed an association with negative symptom improvement at 6 week.

Meta-analysis and Power Test

Six studies from Table 3, including ours, with accessible genotyping data for Cys23Ser and binary outcome for positive symptom improvement in EUR, were included in a meta-analysis. We reported the overall odds ratio is 2.00 (95%CI, 1.38–2.91, $p = 0.0003$) or 1.94 (95%CI, 1.27–2.99, $p = 0.0024$) under the fixed or random effect models, respectively (Figure 2). The heterogeneity between the studies was insignificant (Cochran’s Q = 6.03, $p = 0.30$; $I^2 = 0.17$ (95% CI, 0.00 to 0.62). QUANTO 1.2 was used to calculate the power of the test. The Ser23 carriers were found to have a frequency of 0.15 to 0.45 according to Table 3. As Ser23 carriers increased the odds of having treatment response by 2.0, population risk ($Kp$) = 0.30, dominant mode of inheritance, and 216 responders/738 non-responders were genotyped, the power (chance) to detect an association with significance $p < 0.01$ was over 90%.

DISCUSSION

We tested the association between the HTR2C polymorphisms, Cys23Ser, −759C/T, and −697G/C, and treatment response in 171 schizophrenic patients after treatment with APDs, mainly clozapine, for 6 months. One of the strengths of this study was that the majority of the patients were unmedicated at the time of initial assessment. Both Ser23 and −759C–Ser23 haplotype were significantly associated with positive and negative symptom improvement in male patients and Cys23Ser, not the promoter polymorphisms, is the major genetic contributor of the HTR2C in modulating symptom improvement to clozapine. The previously published association studies (Table 3) showed no consistent results. Attempted replication studies (37, 46) for Sodhi et al.’s (33) reported negative results, but the individual $p$-values as well as the $p$-value from a meta-analysis (47) were suggestive of a trend for association (Masellis, $p = 0.18$, Vehof, $p = 0.13$, and Gressier, $p = 0.12$). Our meta-analysis of six original studies (33, 35–37, 46) suggests that HTR2C Cys23Ser is associated with symptom improvement after treatment with clozapine. This is consistent with a previous meta-analysis that included several APDs (48).

Some atypical APDs, e.g., clozapine, olanzapine, risperidone, and sertindole, are potent inverse agonists of both HTR2C and HTR2A receptors (49, 50). On the other hand, some typical APDs, e.g., chlorpromazine, thioridazine, spiperone, and thiothixene, are HTR2C neutral antagonists, which would preclude their affecting the constitutive activity of HTR2Cs, although the combination of a neutral antagonist and inverse agonist, could lead to blockade of the neutral antagonist (51). The Ki (nM) for D2, HTR2A, and HTR2C are provided in Table 3.

One of the strengths of this study was that the majority of the patients were unmedicated at the time of initial assessment. Both Ser23 and −759C–Ser23 haplotype were significantly associated with positive and negative symptom improvement in male patients and Cys23Ser, not the promoter polymorphisms, is the major genetic contributor of the HTR2C in modulating symptom improvement to clozapine. This is consistent with a previous meta-analysis that included several APDs (48).

Some atypical APDs, e.g., clozapine, olanzapine, risperidone, and sertindole, are potent inverse agonists of both HTR2C and HTR2A receptors (49, 50). On the other hand, some typical APDs, e.g., chlorpromazine, thioridazine, spiperone, and thiothixene, are HTR2C neutral antagonists, which would preclude their affecting the constitutive activity of HTR2Cs, although the combination of a neutral antagonist and inverse agonist, could lead to blockade of the neutral antagonist (51). The Ki (nM) for D2, HTR2A, and HTR2C are provided in Supplementary Table 5 for each APD (51). Studies based mainly on a single APD are more likely to generate positive results than those based on diverse drug treatments because APDs can produce variable effects on non-5-HT2C, receptors which can affect their actions as antipsychotics and cognitive enhancers (49, 50). However, the meta-analysis reported here suggests our findings may generalize to atypical APDs which are HTR2C antagonists or inverse agonists at clinically effective doses.

Many factors may contribute to the inconsistent results in pharmacogenetic studies of APD response. These include the heterogeneity in patient populations, utilization of different rating scales, definition of response, frequency of genetic variants in distinct ethnic groups, APDs which differ with regard to...
### TABLE 2

| SNP ID | Haplotype | Haplotype frequency | BPRS positive 3 items | BPRS positive 4 items | BPRS negative 3 items |
|--------|-----------|---------------------|----------------------|----------------------|----------------------|
|        |           |                     | Male ONLY            | Male ONLY            | Male ONLY            |
| Cys23Ser(rs6318) | Ser carrier | 0.22                | 0.22                 | 0.22                 | 0.22                 |
|        | rs3813929-rs6318 C-Ser | 0.202               | 0.202               | 0.202               | 0.202               |
|        | rs3813929-rs518147-rs6318 Ser/ Ser | 0.34                 | 0.34                 | 0.34                 | 0.34                 |

A. Haplotype association analysis of HTR2C SNPs with treatment response at 6mon by Chi-square. Positive 4-item includes suspiciousness, hallucinatory behavior, unusual thought content, and conceptual disorganization. Positive 3-item excludes “concept disorganization.” Male and female subjects were analyzed separately. B. Ser23 carriers have better symptom improvement in male subjects. All data was presented as Mean change (absolute change), which is calculated by (6-week or 6-month Baseline); & represents F statistic and p-value calculated from ANCOVA on Delta1 change at 6 week or 6 month after controlling for race, drugs, age of onset, and the corresponding baseline psychopathology. # represents the result from Levene’s test of equality of error variances with p ≤ 0.05, which against the null hypothesis that the error variance of the dependent variable is equal across groups, suggesting ANCOVA assuming homogeneity of variance is rejected.
Table 3: A meta-analysis of six studies to determine the general relationship between HTR2C Cys23Ser and drug response to APDs.

| Reference   | Male/Female | Antipsychotics            | Ethnicity                        | Study duration | Genetic variants |Responder/non-trait responder | Statistical analysis                                                                 | Summary of the result (p < 0.05, uncorrected for multiple testing) |
|-------------|-------------|---------------------------|----------------------------------|----------------|------------------|-------------------------------|--------------------------------------------------------------------------------------|---------------------------------------------------------------------|
| Sodhi et al.* (33) | 162 (unclear) | Clozapine only            | Caucasian                        | 3 months       | rs6318           | 103/59                        | Global assessment scale, 20 point improvement as cutoff for response (binary trait) or raw changes (quantitative trait) | Anova, p = 0.002; Dominant mode, X² = 7.7, p = 0.005                  |
| Masellis et al.* (37) | 185 (132/53) | Clozapine only            | Caucasian/African-American       | 6 months       | rs6318           | 72/67                         | A reduction of ≥ 20% in total BPRS score (binary trait)                              | X² = 3.46, p = 0.18 for Caucasians; X² = 0.31, p = 0.86 for African-American |
| Arranz et al. (34) | 200 (unclear) | Clozapine only            | Caucasian                        | 3 months       | -330(GT)/-244(CT); rs6318 | 133/67                        | Global assessment scale, 20 point improvement as cutoff for response (binary trait) or raw changes (quantitative trait) | Dominant genetic model. Chi-square, hemizygous males and homozygous females grouped together |
| Reynolds et al. (18) | 117 (58/59) | Chlorpromazine (56.4%); risperidone (36.8%); clozapine (3.4%); fluphenazine (2.6%); sulpiride (1%) | Chinese (Han)                      | 2.5 months     | rs3813929        | 86/90                         | % change of PANSS (positive, negative, general) (quantitative trait); A reduction of ≥50% in total PANSS score (binary trait) | Anova test to determine any association with genotype of the percentage change in PANSS score. Any significant result was then followed by analysis to determine which subscores of PANSS contribute to the overall difference. Stepwise regression analysis to determine the influence of clinical and demographic factors on symptom measures. |
| Ikeda (44)  | 120 (58/62) | Risperidone only          | Japanese                         | 2.5 months     | rs3813929; rs518147 | Not available                | % change in PANSS (positive, negative, general) (quantitative trait)                | Anova, p = 0.023 for negative subscore; p = n.s. for positive subscore. Chi-square, When separate male and female, this significant association only in male subjects (p = 0.007) |
| Need (45)   | 524 (CATIE Phase 1) | Olanzapine, perphenazine, quetiapine, risperidone and ziprasidone | Caucasian/African-American       | 3 months       | 30 tag SNPs in HTR2C | Not available                | Delta change of PANSS (positive, negative, general) (quantitative trait)            | All drug groups analyzed together using linear regression with additive genetic model and including eigenstrat axis, sex, self-described race, baseline, and phase I drug as covariates |

(Continued)
| Reference          | Male/female | Antipsychotics | Ethnicity       | Study duration | Genetic variants | Responder/non-trait responder | Statistical analysis                              | Summary of the result (p < 0.05, uncorrected for multiple testing) |
|--------------------|-------------|----------------|----------------|----------------|------------------|-----------------------------|---------------------------------------------------|--------------------------------------------------------------------|
| Li et al. (19)     | 130 (45/85) | Risperidone only | Chinese (Han)  | 2 months       | rs3813929; rs518147; rs1023574; rs9692890; rs6318 | Not available | % change of total BPRS score (quantitative trait)   | Anova test for the genetic association with risperidone efficiency in the female and male group, respectively. Dominant genetic model to the regression analysis. |
| Vehof et al.* (46) | 329 (260/69); actual number is 293 (-/-) for rs3813929 and 297 for rs6318 | Clozapine (9.1%); Olanzapine (24.3%); Risperidone (22.8%); Quetiapine (5.5%); Haloperidol (7.3%); Multiple (11.2%); Aripiprazole (1.5%); others (6.7%) | Caucasian | variable | rs3813929; rs6318 | 247/82 | Clinical Global Impression—Improvement scale positive symptoms (binary and quantitative trait) | Ordinal regression analysis (additive model) corrected for age and gender. Hemizygous males and homozygous females grouped together. |
| Malhotra et al.* (35) | 66 (49/17) | Clozapine only | Caucasian | 2.5 months | rs6318 | 18/48 | A reduction of ≥20% in total BPRS score (binary trait) | Fisher Exact test | p = 0.30 |
| Rietschel et al.* (36) | 152 (78/76) | Clozapine only | Caucasian | variable (Avg = 2.0 months) | rs6318 | 110/42 | Self defined four different groups from group 0 (worsening/no change), 1 (slight improvement), 2 (marked improvement), 3 (total reduction) | Chi-square separated by male and female. | X² =2.161, p = 0.142, A trend of Ser in responder (24%) than in non-responder (15%) |
| Li and Meltzer*     | 171 (115/56) | Clozapine (78%); Olanzapine (2.1%); Risperidone (3.8%); Melperone (7.0%); Others (9.0%) | Caucasian/African-American | 6 weeks & 6 months | rs3813929; rs518147; rs6318 | 74/63 (in terms of positive symptom at 6 month) | A reduction of ≥20% in total BPRS score (binary trait); absolute change (Δ) in BPRS total score and subscales (quantitative trait) | Chi-square separated by male and female; Linear regression adjusting for covariates; ANCOVA adjusting for covariates; Individual SNP association and Haplotype association tests | In male patients, X² =7.54, p = 0.01 for rs6318 in association with positive symptoms response at 6mon; X² =7.80, p = 0.03 in association with negative symptoms response at 6mon. |

Previous association studies of HTR2C polymorphisms with treatment response to antipsychotics, mainly clozapine, in Schizophrenia. *represents studies included in the meta-analysis.
HTR2C pharmacology and actions on other receptors which impact response, e.g., D2, 5-HT1A, and alpha 2 adrenoreceptors, duration of clinical assessment, proposed mode of inheritance, and statistical methods.

In vitro functional studies provide a partial explanation of why Cys23Ser has a main effect on response to APD treatment. Ser23 receptor displayed greater constitutive activity to mobilize calcium than Cys23 receptor (52). Ser23 receptor had greater cell surface expression and more rapid resensitization following exposure to SB206553, a mixed HTR2B antagonists and HTR2C inverse agonist (53). It may be concluded that prolonged exposure of both HTR2C isoreceptors to an inverse agonist increases receptor responsiveness to endogenous 5-HT or other HTR2C agonists, and cells or presumably individuals carrying Ser23 have prompter response to the stimuli than Cys23 carriers. Dopaminergic circuitry is more sensitive to pain stress in Ser23 carriers (54). Greater dopamine release in the nucleus accumbens, caudate nucleus, and putamen was observed in the Ser23 carriers during pain, suggesting mesoaccumbal stress sensitivity may mediate the effects of HTR2C variation on the risk of neuropsychiatric disorders. Significant differences in regional cerebral blood flow between Ser23 and Cys23 male carriers after treatment with serotonin agonist meta-Chlorophenylpiperazine suggests that this polymorphism does have distinct functional consequences (55).

In conclusion, these results provide additional evidence that HTR2C polymorphisms, particularly Cys23Ser, are associated with response to APD treatment, mainly clozapine with HTR2C antagonism or partial agonism, in male schizophrenic patients.

ETHICS STATEMENT

This study was carried out in accordance with the recommendations of Internal Review Board of Vanderbilt University and Case Western Reserve University with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Internal Review Board of Vanderbilt University and Case Western Reserve University.

AUTHOR CONTRIBUTIONS

JL mostly contributed to data analysis, interpretation of results, and manuscript writing. HH contributed to initial data analysis and manuscript writing. HM has designed the study and written the manuscript in close collaboration with JL. All authors have approved the final manuscript.

FUNDING

This research was supported by donations from the Weisman Family, Mr. Michael Burke, and Mr. Michael Shmerling. Neither had any role in study design, data collection, analysis and interpretation, writing of the report, or the decision to submit the paper for publication.

ACKNOWLEDGMENTS

This study was first presented at the Annual Meeting of American Society of Human Genetics in 2014 as a poster presentation and the abstract was collected at www.ashg.org/2014meeting/abstracts/fulltext/f140120372.htm.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2019.00058/full#supplementary-material
REFERENCES

1. Di Giovanni G, De Deurwaerdere P, Di Mascio M, Di Matteo V, Esposito E, Stampinato U. Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience (1999) 91:587–97. doi: 10.1016/S0306-4522(98)00655-1

2. Marquis KL, Sabb AL, Logue SE, Brennan JA, Piesja MJ, Comery TA, et al. WAY-163909 [75R,10aR]-1,2,3,4,8,9,10a-octahydro-7H-cyclopenta-b[1,4]diazepino[6,7,1hi]indole: a novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity. J Pharmacol Exp Ther. (2007) 320:486–96. doi: 10.1121/jpet.1060989

3. Boothman L, Raley J, Denk F, Hirani E, Sharp T. In vivo evidence that 5-HT(2C) receptors inhibit 5-HT neuronal activity via a GABAAergic mechanism. Br J Pharmacol. (2006) 149:861–9. doi: 10.1038/sj.bjp.0706935

4. Calcagno E, Carli M, Baviera M, Invernizzi RW. Endogenous serotonin and serotonin2C receptors are involved in the ability of M100907 to suppress cortical glutamate release induced by NMDA receptor blockade. J Neurochem. (2009) 108:521–32. doi: 10.1111/j.1471-4159.2008.07589.x

5. Howes OD, Williams M, Ibrahim K, Leung G, Egerton A, McGuire PK, et al. Midbrain dopamine function in schizophrenia and depression: a post-mortem and positron emission tomographic imaging study. Brain (2013) 136:2342–51. doi: 10.1093/brain/awt264

6. Di Matteo V, De Blasi A, Di Giulio C, Esposito E. Role of 5-HT(2C) receptors in the control of central dopamine function. Trends Pharmacol Sci. (2001) 22:229–32. doi: 10.1016/S0165-6147(00)01688-6

7. Santana N, Artigas F. Laminar and cellular distribution of monoamine receptors in rat medial prefrontal cortex. Front Neuroanat. (2017) 11:87. doi: 10.3389/fnana.2017.00087

8. Thomas EHX, Bozoglu K, Rossell SL, Gurvich C. In vivo imaging of the glutamatergic system on cognition in schizophrenia: a systematic review. Neurosci Biobehav Rev. (2017) 77:369–87. doi: 10.1016/j.neubiorev.2017.04.005

9. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology (1999) 38:1083–152. doi: 10.1006/s0022-3969(99)00106-6

10. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in the control of central dopamine function. J Neurochem. (2007) 105:236–8. doi: 10.1002/ajmg.1260

11. Murad I, Kremer I, Dobrusin M, Muhaheed M, Bannoura I, Muller DJ, et al. A family-based study of the Cys23Ser 5HT2C serotonin receptor polymorphism in schizophrenia. Am J Med Genet. (2001) 105:236–8. doi: 10.1002/ajmg.1260

12. Meltzer HY, Huang M. Serotonin2C receptors are involved in the ability of M100907 to suppress cortical glutamate release induced by NMDA receptor blockade. J Neurochem. (2009) 108:521–32. doi: 10.1111/j.1471-4159.2008.07589.x
Li et al.

37. Masellis M, Basile V, Meltzer HY, Lieberman JA, Sevy S, Macciardi FM, et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology (1998) 19:123–32. doi: 10.1016/S0893-133X(98)00067-4

38. Meltzer HY. Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Arch Gen Psychiatry (1989) 46:672. doi: 10.1001/archpsyc.1989.01810070098017

39. Meltzer HY, Brennan MD, Woodward ND, Jayathilake K. Association of Sult4A1 SNPs with psychopathology and cognition in patients with schizophrenia or schizoaffective disorder. Schizophr Res. (2008) 106:258–64. doi: 10.1016/j.schres.2008.08.029

40. Meltzer HY, Brennan MD, Woodward ND, Jayathilake K. Association of Sult4A1 SNPs with psychopathology and cognition in patients with schizophrenia or schizoaffective disorder. Schizophr Res. (2008) 106:258–64. doi: 10.1016/j.schres.2008.08.029

41. Kane J, Homigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry (1988) 45:789–96. doi: 10.1001/archpsyc.1988.01800330013001

42. Colantuoni C, Lipska BK, Ye T, Hyde TM, Tao R, Leek JT, et al. Temporal dynamics and genetic control of transcription in the human prefrontal cortex. Nature (2011) 478:519–23. doi: 10.1038/nature10524

43. Numata S, Ye T, Hyde TM, Guitart-Navarro X, Chen Y, Ertugrul A, et al. HTR2C Associated With Antipsychotic Response in the CATIE trial: a candidate gene analysis. Pharmacogenetics (2008) 18:260–72. doi: 10.1016/j.ejhg.2011.12.020

44. Ikeda M, Yamanouchi Y, Kinoshita Y, Kitajima T, Yoshimura R, Hashimoto S, et al. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics (2008) 9:1347–43. doi: 10.2217/14622416.9.10.1347

45. Need AC, Keefe RS, Ge D, Grossman I, Dickson S, McEvoy JP, et al. Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. Eur J Hum Genet. (2009) 17:946–57. doi: 10.1038/ejhg.2008.264

46. Vehof J, Burger H, Wilfert B, Al Hadithy A, Alizadeh BZ, Snieder H. Clinical response to antipsychotic drug treatment: association study of polymorphisms in six candidate genes. Eur Neuropsychopharmacol. (2012) 22:625–31. doi: 10.1016/j.eurneuro.2012.01.006

47. Gressier F, Porcelli S, Calati R, Serretti A. Pharmacogenetics of clozapine response and induced weight gain: a comprehensive review and meta-analysis. Eur Neuropsychopharmacol. (2016) 26:163–85. doi: 10.1016/j.eurneuro.2015.12.035

48. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry (2004) 9:442–73. doi: 10.1038/sj.mp.4001494

49. Rauser L, Savage JE, Meltzer HY, Roth BL. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther. (2001) 299:83–9.

50. Kroeze WK, Hufiesen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology (2003) 28:519–26. doi: 10.1038/sj.npp.1300027

51. Herrick-Davis K, Grinde E, Teitler M. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J Pharmacol Exp Ther. (2000) 295:226–32.

52. Okada M, Northup JK, Ozaki N, Russell JT, Linnoila M, Goldmärr D. Modification of human 5-HT(2C) receptor function by Cys23Ser, an abundant, naturally occurring amino-acid substitution. Mol Psychiatry (2004) 9:55–64. doi: 10.1038/sj.mp.4001357

53. Walstab J, Steinhagen F, Bruss M, Gothert M, Bonisch H. Differences between human wild-type and C23S variant 5-HT2C receptors in inverse agonist-induced desensitization. Pharmacol Rep. (2011) 63:45–53. doi: 10.1016/S1734-1140(11)70397-8

54. Mickey BJ, Sanford BJ, Love TM, Shen PH, Hodgkinson CA, Stohler CS, et al. Striatal dopamine release and genetic variation of the serotonin 2C receptor in humans. J Neurosci. (2012) 32:9344–50. doi: 10.1523/JNEUROSCI.1260-12.2012

55. Kuhn KU, Joe AY, Meyer K, Reichmann K, Mai B, Lanz M, et al. Neuroimaging and 5-HT2C receptor polymorphism: a HMPAO-SPECT study in healthy male probands using mCPP-challenge of the 5-HT2C receptor. Pharmacopsychiary (2004) 37:286–91. doi: 10.1055/s-2004-832685

Conflict of Interest Statement: HM is a stockholder in SureGene and ACADIA and receives additional grant support from Sunovion and Sumitomo Dainippon Pharma for other studies. HM also receives grant support from Alkermes, Auspex, Boehringer Mannheim, Eli Lilly, Janssen, Lundbeck, Mag T, Otsuka, and Reviva.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Li, Hashimoto and Meltzer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.